Hematologist
CION Cancer Clinics
Blinatumomab and inotuzumab for adults with ALL | CION Cancer Clinics
Blinatumomab and inotuzumab are antibody drugs for adults with B-cell ALL. They are mainly used when leukaemia returns, resists chemotherapy or is still detectable after treatment, often on the way to a transplant. Blinatumomab is approved in India, inotuzumab can be harder to access, and both are costly and need close monitoring. This page explains how each works, how it is given, which side effects matter and what to ask your team. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What are blinatumomab and inotuzumab, and when are they used?
- How do the two drugs compare?
- In which situations might your team suggest one?
- What does a course of blinatumomab involve?
- Can you get these drugs in India, and how is it paid for?
- What do families often assume about these newer drugs?
- Which words will you meet on the reports?
- Common questions about blinatumomab and inotuzumab
The short answer
What are blinatumomab and inotuzumab, and when are they used?
Blinatumomab and inotuzumab ozogamicin are antibody drugs for B-cell acute lymphoblastic leukaemia (ALL) in adults. They are mainly used when leukaemia has come back, has not responded to chemotherapy, or is still detectable on a sensitive test after treatment. Blinatumomab is approved in India. Access to inotuzumab can be more limited. Both are expensive and not right for everyone.
How they differ from chemotherapy
Chemotherapy attacks dividing cells in general, healthy or not. These drugs look for a specific marker on the surface of B-cell leukaemia cells. Blinatumomab looks for a marker called CD19. Inotuzumab looks for one called CD22. That makes them more targeted, although they bring side effects of their own.
Who they do not suit
They are not used for T-cell ALL, because those cells do not carry the right markers. They may not suit people whose leukaemia cells have lost the marker, or people with certain liver, nerve or infection problems. Your haematologist checks the marker on your latest bone marrow report before recommending either.
Neither drug is a replacement for the whole treatment plan. They are usually one part of it, often leading towards a transplant.Side by side
How do the two drugs compare?
Blinatumomab
Inotuzumab ozogamicin
Links your own T-cells to leukaemia cells carrying CD19
Carries a toxic drug straight into cells carrying CD22
Given as a continuous drip through a small portable pump
Given as a short drip on set days of each cycle
Main concerns: fever with low blood pressure, confusion, fits
Main concern: liver damage, especially around transplant
Used after relapse, for MRD-positive disease and in some first-line plans
Used mainly after relapse, and in some gentler plans for older adults
Not sure whether this applies to you?
Ask an oncologistWhere they fit
In which situations might your team suggest one?
The choice depends on why the drug is being considered, the markers on the leukaemia cells and whether a transplant is planned.
Leukaemia still detectable after treatment
When a minimal residual disease (MRD) test still finds leukaemia in remission, blinatumomab can clear it in many people and make a transplant safer.
Relapsed or resistant leukaemia
Either drug may be used to bring the leukaemia back into remission, usually as a bridge to a donor transplant or to CAR-T therapy at a specialised centre.
As part of first treatment
Newer plans add blinatumomab to chemotherapy for some adults with Philadelphia-negative B-cell ALL, or pair it with a targeted tablet in Philadelphia-positive ALL.
Ask whether this is approved and accessible for your case in India.Older or less fit adults
Combined with lower-intensity chemotherapy, these drugs can reduce the amount of harsh treatment needed.
Checked first
- Liver function
- Heart and kidney health
- Any history of fits or nerve problems
What to expect
What does a course of blinatumomab involve?
-
A line and a pump
A thin tube is placed in a vein, usually in the arm or chest. The drug runs through it day and night from a small pump you carry in a bag.
-
The first days in hospital
The start of each course is watched closely, because fever, low blood pressure and confusion are most likely then. A steroid is often given beforehand to reduce these reactions.
-
Continuing at home or in day-care
Once settled, many people go home with the pump. Bags are changed at set visits. The pump must not be stopped, disconnected or flushed at home.
-
A planned break
Each cycle ends with a break without the drug. A bone marrow test checks the response.
-
The next step
Depending on the result, further cycles, a transplant referral or another treatment is discussed.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
In India
Can you get these drugs in India, and how is it paid for?
Blinatumomab is approved and supplied in India. Inotuzumab may be harder to obtain, and some centres arrange it through the manufacturer or an import route, so ask about current availability. Both are among the costliest medicines in blood cancer care. Whether a person can receive them usually depends on cost, cover and access, as much as on the medical reasons.
When a cheaper route may be reasonable
These drugs are not the only way forward. For some people, a different chemotherapy combination, a clinical trial or moving straight to transplant planning may be just as sensible. Ask the team to explain the alternatives side by side, including what each would mean for time in hospital, travel and the family's finances.
What affects the cost
The number of cycles, body weight, hospital days for monitoring, and whether a transplant follows all change the total. Any figure quoted before the plan is fixed is an estimate, not a quote.
Schemes and support
Aarogyasri, PM-JAY, CGHS, ECHS, EHS and cashless insurance cover some leukaemia treatment, but newer drugs are not always included in the package. Manufacturers sometimes run patient access programmes. Rules change, so check your current entitlement before treatment starts.
What to ask your team
Ask why this drug is being suggested over other options, how many cycles are expected, what monitoring it needs, and what the plan is if it cannot be afforded. CION's haematology team evaluates the case, presents it at a tumour board and coordinates access with qualified centres. Your treating team decides whether a drug is right for you.
Commonly believed
What do families often assume about these newer drugs?
"Newer and costlier means it will work where chemotherapy did not."
These drugs help many people, but not everyone responds. Your leukaemia's markers and the reason for using the drug matter more than how new it is.
"Antibody drugs are gentle, so there is nothing to watch."
Blinatumomab can cause high fever, low blood pressure and confusion. Inotuzumab can harm the liver. Both need close monitoring, especially early on.
"If blinatumomab works, a transplant is no longer needed."
Sometimes, but often it is used to reach a deep remission before a transplant. The team weighs your risk group and fitness.
"We can buy it privately and have it given anywhere."
These drugs need a haematology team ready to manage reactions quickly. Giving them without that support is unsafe.
On your report
Which words will you meet on the reports?
- CD19 and CD22
- Markers on the surface of B-cells. The marrow report says whether your leukaemia cells carry them.
- Cytokine release syndrome (CRS)
- A strong immune reaction causing fever, chills and low blood pressure. It is watched for at the start of blinatumomab.
- Neurotoxicity
- Effects on the brain such as confusion, shaking, trouble speaking or fits. Report any change the same day.
- VOD or SOS
- Veno-occlusive disease, now also called sinusoidal obstruction syndrome. Blocked small veins in the liver, a known risk with inotuzumab.
- Refractory
- Leukaemia that has not responded to treatment.
Questions we are asked
Common questions about blinatumomab and inotuzumab
Is blinatumomab available in India?
Yes. Blinatumomab is approved and supplied in India, and it is used in several cancer centres. Access depends on the reason it is prescribed, the cost and your cover. Ask your haematologist whether it suits your situation and what the practical route to getting it would be.
Can we carry the blinatumomab pump at home?
Often yes, after the first days of monitoring in hospital. You carry the pump in a small bag and come in for bag changes. Keep the line dry and never stop or disconnect the pump yourself. If it alarms or leaks, call the team straight away.
What signs mean we should go to hospital?
Go to the nearest emergency department the same day, or call 108, for high fever, shivering, dizziness or fainting, confusion, trouble speaking, shaking or a fit. For inotuzumab, add yellow eyes, a swollen tummy or sudden weight gain. Say which drug the person is receiving.
Will there be hair loss or sickness?
Hair loss is less common with these drugs alone than with standard chemotherapy. Tiredness, fever, headache and feeling sick can happen. If they are combined with chemotherapy, the chemotherapy's effects apply too. Ask the team which effects to expect for your exact plan.
Why is liver testing so important with inotuzumab?
Inotuzumab can block small veins in the liver. The risk is higher if a transplant follows soon after, so the team plans the number of cycles and the transplant timing carefully. Regular blood tests help catch early changes.
Does it work for T-cell ALL?
No. Both drugs target markers found on B-cells, so they are not used for T-cell ALL. People with T-cell ALL have other options, which their haematologist can explain. The type of ALL is written on the bone marrow report, often as B-ALL or T-ALL.
Can these drugs be used before a transplant?
Yes, that is one of their main uses. They can help reach remission, or clear leukaemia still detectable on a sensitive test, so that a transplant can go ahead. CION does not perform transplants itself, and coordinates referral to qualified centres where one is advised.
What if we cannot afford them?
Say so early. There may be other effective treatments, patient access programmes or scheme cover to explore. A good plan is one the family can complete. Your haematologist would rather adjust the approach than see treatment stopped halfway because of cost.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Blinatumomab
- National Cancer Institute — Adult Acute Lymphoblastic Leukemia Treatment (PDQ), Patient Version
- NICE — Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)
- NICE — Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Acute Lymphoblastic Leukaemia in AdultsThe overview of adult ALL, from diagnosis onwardsMRD-Guided Treatment in Adult ALLThe test that often decides whether blinatumomab is usedRelapsed Adult ALL: CAR-T and Other OptionsWhere these drugs sit among relapse optionsAdult ALL Treatment Cost in IndiaWhat shapes the total bill and which schemes help
Talk to us
Has one of these drugs been suggested?
Tell us what has been found so far. CION's haematology team will go through the options with you and help you reach the right specialist. One helpline serves every CION centre.